Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
SUN PHARMA | LUPIN LTD | SUN PHARMA/ LUPIN LTD |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.8 | 41.9 | 61.6% | View Chart |
P/BV | x | 2.7 | 2.6 | 105.3% | View Chart |
Dividend Yield | % | 0.5 | 0.6 | 72.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-18 |
LUPIN LTD Mar-18 |
SUN PHARMA/ LUPIN LTD |
5-Yr Chart Click to enlarge
|
||
High | Rs | 701 | 1,465 | 47.8% | |
Low | Rs | 433 | 727 | 59.6% | |
Sales per share (Unadj.) | Rs | 110.4 | 349.6 | 31.6% | |
Earnings per share (Unadj.) | Rs | 11.0 | 5.6 | 197.5% | |
Cash flow per share (Unadj.) | Rs | 17.2 | 29.6 | 58.3% | |
Dividends per share (Unadj.) | Rs | 2.00 | 5.00 | 40.0% | |
Dividend yield (eoy) | % | 0.4 | 0.5 | 77.3% | |
Book value per share (Unadj.) | Rs | 158.8 | 300.3 | 52.9% | |
Shares outstanding (eoy) | m | 2,399.26 | 452.08 | 530.7% | |
Bonus/Rights/Conversions | - | ESOPS | - | ||
Price / Sales ratio | x | 5.1 | 3.1 | 163.8% | |
Avg P/E ratio | x | 51.6 | 197.2 | 26.2% | |
P/CF ratio (eoy) | x | 32.9 | 37.1 | 88.8% | |
Price / Book Value ratio | x | 3.6 | 3.6 | 97.8% | |
Dividend payout | % | 18.2 | 90.0 | 20.3% | |
Avg Mkt Cap | Rs m | 1,360,021 | 495,502 | 274.5% | |
No. of employees | `000 | 17.8 | 17.0 | 104.4% | |
Total wages/salary | Rs m | 53,671 | 28,647 | 187.4% | |
Avg. sales/employee | Rs Th | 14,890.9 | 9,273.6 | 160.6% | |
Avg. wages/employee | Rs Th | 3,017.1 | 1,681.0 | 179.5% | |
Avg. net profit/employee | Rs Th | 1,480.6 | 147.4 | 1,004.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 264,895 | 158,042 | 167.6% | |
Other income | Rs m | 8,388 | 1,504 | 557.9% | |
Total revenues | Rs m | 273,282 | 159,545 | 171.3% | |
Gross profit | Rs m | 56,081 | 31,475 | 178.2% | |
Depreciation | Rs m | 14,998 | 10,859 | 138.1% | |
Interest | Rs m | 5,176 | 2,044 | 253.3% | |
Profit before tax | Rs m | 44,295 | 20,076 | 220.6% | |
Minority Interest | Rs m | 0 | -71 | 0.0% | |
Prior Period Items | Rs m | 0 | 35 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | -9,505 | -14,644 | 64.9% | |
Tax | Rs m | 8,452 | 2,885 | 293.0% | |
Profit after tax | Rs m | 26,338 | 2,513 | 1,048.2% | |
Gross profit margin | % | 21.2 | 19.9 | 106.3% | |
Effective tax rate | % | 19.1 | 14.4 | 132.8% | |
Net profit margin | % | 9.9 | 1.6 | 625.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 316,359 | 122,095 | 259.1% | |
Current liabilities | Rs m | 198,643 | 50,956 | 389.8% | |
Net working cap to sales | % | 44.4 | 45.0 | 98.7% | |
Current ratio | x | 1.6 | 2.4 | 66.5% | |
Inventory Days | Days | 95 | 85 | 112.1% | |
Debtors Days | Days | 108 | 120 | 89.8% | |
Net fixed assets | Rs m | 213,178 | 129,876 | 164.1% | |
Share capital | Rs m | 2,399 | 904 | 265.4% | |
"Free" reserves | Rs m | 378,606 | 134,866 | 280.7% | |
Net worth | Rs m | 381,006 | 135,771 | 280.6% | |
Long term debt | Rs m | 17,721 | 64,245 | 27.6% | |
Total assets | Rs m | 643,028 | 263,054 | 244.4% | |
Interest coverage | x | 9.6 | 10.8 | 88.3% | |
Debt to equity ratio | x | 0 | 0.5 | 9.8% | |
Sales to assets ratio | x | 0.4 | 0.6 | 68.6% | |
Return on assets | % | 4.9 | 1.7 | 283.0% | |
Return on equity | % | 6.9 | 1.9 | 373.5% | |
Return on capital | % | 10.0 | 3.7 | 269.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 40,816 | 53,141 | 76.8% | |
Fx outflow | Rs m | 30,143 | 19,335 | 155.9% | |
Net fx | Rs m | 10,673 | 33,807 | 31.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 39,072 | 17,512 | 223.1% | |
From Investments | Rs m | -33,708 | -14,073 | 239.5% | |
From Financial Activity | Rs m | -15,393 | -14,921 | 103.2% | |
Net Cashflow | Rs m | -7,359 | -11,482 | 64.1% |
Indian Promoters | % | 63.7 | 46.6 | 136.7% | |
Foreign collaborators | % | 0.0 | 0.2 | - | |
Indian inst/Mut Fund | % | 5.1 | 11.3 | 45.4% | |
FIIs | % | 23.0 | 31.9 | 72.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 8.3 | 10.1 | 82.2% | |
Shareholders | 133,026 | 98,259 | 135.4% | ||
Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: PLETHICO PHARMA BIOCON LTD J.B.CHEMICALS ALKEM LABORATORIES AJANTA PHARMA
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
| |
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.
For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.
More Views on NewsThe real estate sector is ready to make a comeback. This is the stock to consider buying.
During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More
| |